CETRAXAL

This brand name is authorized in United States. It is also authorized in Ecuador, Finland, Israel, Poland, Singapore, Spain, UK.

Active ingredients

The drug CETRAXAL contains one active pharmaceutical ingredient (API):

1	Ciprofloxacin UNII 4BA73M5E37 - CIPROFLOXACIN HYDROCHLORIDE
	Ciprofloxacin is a fluoroquinolone antibacterial agent. The bactericidal action of ciprofloxacin results from the inhibition of both type II topoisomerase (DNA-gyrase) and topoisomerase IV, required for bacterial DNA replication, transcription, repair and recombination.
	Read more about Ciprofloxacin

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
CETRAXAL Ear drops	MPI, EU: SmPC	Medicines & Healthcare Products Regulatory Agency (GB)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
S02AA15	Ciprofloxacin	S Sensory organs → S02 Otologicals → S02A Antiinfectives → S02AA Antiinfectives
Discover more medicines within S02AA15

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
EC	Agencia Nacional de Regulación, Control y Vigilancia Sanitaria	984-MEE-0515
ES	Centro de información online de medicamentos de la AEMPS	60883, 62602, 67925
FI	Lääkealan turvallisuus- ja kehittämiskeskus	382449
GB	Medicines & Healthcare Products Regulatory Agency	349407
IL	מִשְׂרַד הַבְּרִיאוּת	8668
PL	Rejestru Produktów Leczniczych	100279921
SG	Health Sciences Authority	14596P, 14597P
US	FDA, National Drug Code	66992-450